Ilaris Dosage
Generic name: CANAKINUMAB 150mg in 1mL
Dosage form: injection, powder, lyophilized, for solution
Drug class: Interleukin inhibitors
Medically reviewed by Drugs.com. Last updated on Jun 13, 2024.
Recommended Dosage for Cryopyrin-Associated Periodic Syndromes (CAPS)
The recommended weight-based dosage of ILARIS is:
- For patients with CAPS > 40 kg: 150 mg subcutaneously, every 8 weeks
- For patients with CAPS ≥ 15 kg and ≤ 40 kg: 2 mg/kg subcutaneously, every 8 weeks.
- For pediatric patients with CAPS 15 kg to 40 kg with an inadequate response, the dosage can be increased to 3 mg/kg subcutaneously, every 8 weeks.
2.3 Recommended Dosage for Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency (HIDS/MKD), and Familial Mediterranean Fever (FMF)
The recommended weight-based dosage of ILARIS for patients with TRAPS, HIDS/MKD, and FMF is:
- For patients > 40 kg: 150 mg subcutaneously, every 4 weeks. The dosage can be increased to 300 mg every 4 weeks if the clinical response is not adequate.
- For patients ≤ 40 kg: 2 mg/kg administered subcutaneously, every 4 weeks. The dosage can be increased to 4 mg/kg every 4 weeks if the clinical response is not adequate.
Recommended Dosage for Still’s Disease, Including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA)
The recommended weight-based dosage of ILARIS for patients with Still’s Disease (AOSD and SJIA) weighing ≥ 7.5 kg is 4 mg/kg (maximum dose of 300 mg) administered subcutaneously every 4 weeks.
2.5 Recommended Dosage for Gout Flares
The recommended dose of ILARIS for adult patients with a gout flare is 150 mg administered subcutaneously. In patients who require re-treatment, there should be an interval of at least 12 weeks before a new dose of ILARIS may be administered.
2.6 Administration Instructions for ILARIS Injection
STEP 1: ILARIS injection has a concentration of 150 mg/mL. Do not shake. The solution should be essentially free from particulates, clear to opalescent, colorless to slightly brownish-yellow tint. If the solution has a distinctly brown discoloration, is highly opalescent or contains visible particles, do not use.
STEP 2: Using a sterile 1-mL syringe and 18-gauge x 2” needle, carefully withdraw the required volume depending on the dose to be administered and subcutaneously inject using a 27-gauge x 0.5” needle.
Avoid injection into scar tissue as this may result in insufficient exposure to ILARIS.
Discard unused product or waste material in accordance with the local requirements.
More about Ilaris (canakinumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (5)
- Drug images
- Side effects
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: interleukin inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.